Cefoxitin

Cefoxitin
Systematic (IUPAC) name
(6S,7R)-4-(carbamoyloxymethyl)-7-methoxy-
8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-
1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Clinical data
Trade names Mefoxin
AHFS/Drugs.com monograph
MedlinePlus a682737
Pregnancy cat. B
Legal status  ?
Routes IV
Pharmacokinetic data
Metabolism minimal
Half-life 41-59 min
Excretion 85% urine
Identifiers
CAS number 35607-66-0 YesY
ATC code J01DC01
PubChem CID 441199
DrugBank DB01331
ChemSpider 389981 YesY
UNII 6OEV9DX57Y YesY
KEGG D02345 N
ChEBI CHEBI:209807 N
ChEMBL CHEMBL996 N
Chemical data
Formula C16H17N3O7S2 
Mol. mass 427.454 g/mol
SMILES eMolecules & PubChem
 N(what is this?)  (verify)

Cefoxitin is a cephamycin antibiotic developed by Merck & Co., Inc., often grouped with the second−generation cephalosporins. It is sold under the brand name Mefoxin.

Microbiology

Cefoxitin acts by interfering with cell wall synthesis. Its activity spectrum includes a broad range of gram-negative and gram-positive bacteria including anaerobes. It is inactive in vitro to most strains of Pseudomonas aeruginosa and enterococci and many strains of Enterobacter cloacae. Staphylococci resistant to methicillin/oxacillin should be considered resistant to cefoxitin. [1]

Cefoxitin is considered a strong beta-lactamase inducer, as are certain other antibiotics (such as imipenem).[2]

References

  1. ^ Mefoxin Official FDA information at Drugs.com
  2. ^ Phillips I, Shannon K (1993). "Importance of beta-lactamase induction". Eur J Clin Microbiol Infect Dis 12 Suppl 1: S19–26. PMID 8477758.